Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
favezelimab + pembrolizumab + lenvatinib
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is an experimental **combination therapy** of favezelimab (an anti–lymphocyte activation gene-3 monoclonal antibody), pembrolizumab (a programmed death-1 receptor [PD-1] inhibitor), and lenvatinib (a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors, among others). The combination is being evaluated for advanced and metastatic solid tumors, including endometrial cancer, cutaneous squamous cell carcinoma, and potentially several other tumor types. The rationale for the combination lies in dual checkpoint inhibition (LAG-3 and PD-1) to further augment T-cell mediated anti-tumor immunity, combined with the antiangiogenic and immunomodulatory effects of lenvatinib, which may improve immune cell infiltration and efficacy[1][5][7][8].
- Brand names
- Keytruda (pembrolizumab)Lenvima (lenvatinib)
- Other names
- favezelimab + pembrolizumab + lenvatinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on favezelimab + pembrolizumab + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on favezelimab + pembrolizumab + lenvatinib.